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ABSTRACT
OBJECTIVE: The objective of this systematic EBM review is to determine “Are quarterly
fremanezumab injections as effective as monthly fremanezumab injections at reducing the number
of migraine days per month in adults with chronic migraines?”
STUDY DESIGN: A systematic review of three randomized controlled trials (RCTs) that were
peer reviewed and published in English after 2015 comparing quarterly versus monthly
fremanezumab injections in adults 18-70 with chronic migraines.
DATA SOURCE: Three RCTs were obtained from PubMed and selected based on their relevance
to the clinical question and if the RCTs addressed patient oriented outcomes.
OUTCOMES: The three selected RCTs for review, the outcome measured was the mean change
from baseline in the average number of migraine days per month during the 12-week treatment
period after the first dose of fremanezumab using self-reported electronic headache diary entries
by study participants.
RESULTS: All three studies found that quarterly fremanezumab injections were less efficacious
at reducing the mean number of migraine days per month than monthly injections. Silberstein et
al. (2017) reported a reduction from baseline in monthly average migraine days of -4.9 (+/- 0.4)
with quarterly injections and -5.0 (+/- 0.4) with monthly injections. Ferrari et al. (2019) reported
a reduction from baseline in monthly average migraine days of -3.9 ± 0.3 with quarterly injections
and -4.5 ± 0.3 with monthly injections. Goadsby et al. (2020) reported a reduction from baseline
in monthly average migraine days of -6.0 ± 0.3 with quarterly injections -6.0 ± 0.3 with monthly
injections.
CONCLUSIONS: The results of these three studies showed that quarterly fremanezumab is not
as effective as monthly fremanezumab injections at reducing the number of migraine days per
month for individuals with a diagnosis of chronic migraines. However, the difference in mean
reduction of migraine days between the quarterly and monthly injections was less than one day in
all three studies - Silberstein (2017): 0.1 days, Ferrari (2019): 0.6 days, Goadsby (2020): 0.5 days
Due to these results, a conversation with patients pursuing this treatment and shared decision
making would be appropriate regarding whether a monthly or quarterly injection would be most
beneficial on a case-by-case basis.
KEYWORDS: Fremanezumab, Migraines
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INTRODUCTION:
Migraine is a primary headache syndrome which often includes a clinical presentation of
recurrent, unilateral, pulsing, throbbing headache with nausea, photophobia, and phonophobia
that lasts between 4-72 hours.1 Chronic migraine (CM) is defined in individuals with at least 15
headache days per month lasting at least 4 hours per day.1 Consideration for preventative therapy
includes migraine headaches occuring 2-3 times per month or migraine headaches that result in
significant disability.1 CM affects a large number of patients worldwide and can impact the daily
functionality of these individuals. Migraine is a leading cause of disability worldwide with a
prevalence of 15-18%.2,3 Chronic migraine has a prevalence of 2% of the population with
individuals reporting a lower quality of life than those with other less frequent migraine types.3
With the frequency (≥15 days per month) and severity (≥4 hours per day) of symptoms
that CM individuals experience, there is evidence of increased medical resource consumption,
increased cost to the patients, and a significant loss in productivity. There is not an exact
estimate available for the number of healthcare visits each year, however, an analysis of the
International Burden Migraine Study revealed the following odds ratios for healthcare visits
when comparing chronic migraine to episodic migraine: 2.32 (95%, CI 2.15-2.5) primary care
physician visits, 3.23 (95%, CI 3.78-3.75) neurologist/headache specialist visits, 3.01 (95%, CI
2.56-3.55) emergency department visits, 2.84 (95%, CI 1.99-4.06) hospitalizations.5
In addition to the increased utilization of personnel resources, the mean annual cost in the
USA per individual with CM is $8,243.00.4 The direct medical costs, including pharmaceutical
therapy, are reported at $4,943.00 while the indirect cost of lost productivity is reported at
$3,300.00.4 In other reviews, the mean total direct annual cost reported by the International
Burden Migraine Study for individuals with CM in the US is $4,144.005 while the American
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Migraine Prevalence and Prevention study estimated annual productivity related losses at
$5,392.03 for individuals with CM.5
Many of the preventative treatments for CM available were not developed specifically for
migraines and their pathogenesis. Migraine is attributed to neurogenic inflammation,
sensitization, and the resulting headache is attributed to neuronal dysfunction in the trigeminal
system due to a release of vasoactive neuropeptides, of which calcitonin gene-related peptide
(CGRP) is an example.1,6 It can be difficult for patients to find an effective medication, often
resulting in a trial period involving a variety of medications before migraine headaches are under
control.1 Current non-pharmaceutical preventative therapy for CM consists of the avoidance of
triggers, regular sleep, regular meals, hydration, and acupuncture.1 Pharmaceutical therapy for
CM consists of antiepileptics (topiramate, valproic acid), cardiovascular medications
(candesartan, guanfacine, propranolol, verapamil), antidepressants (amitriptyline, venlafaxine),
and botulinum toxin A.1
Most recently, monoclonal antibodies against CGRP have been safely and successfully
used for reducing the number of migraine days. The formulation of these agents targets the
specific pathophysiology of vasoactive neuropeptides.1 These monoclonal antibodies against
CGRP include eptinezumab, erenumab, galcanezumab, and fremanezumab.1 While monthly
subcutaneous injections of fremanezumab, a fully humanized monoclonal antibody that
selectively and effectively binds to CGRP, have proven to be efficacious at reducing migraine
days in individuals with CM2, adjusting to a less frequent dosing schedule may offer cost and
time advantages to the patient. Therefore, this paper evaluates three randomized control trials
(RCTs) comparing the efficacy of the monoclonal antibody, calcitonin gene-related peptide
receptor antagonist, fremanezumab, as a quarterly subcutaneous injection verses its current
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administration of a once monthly subcutaneous injection as preventative therapy for reducing the
number of migraine days per month in individuals with CM.
OBJECTIVE:
The objective of this selective EBM review is to determine “Are quarterly fremanezumab
injections as effective as monthly fremanezumab injections at reducing the number of migraine
days per month in adults with chronic migraines?”
METHODS:
Resources and scholarly literature were selected by the author of this paper based on their
ability to answer the question: Are quarterly fremanezumab injections as effective as monthly
injections at reducing the number of migraine days per month in adults with chronic migraines?
The trials were also selected based on their inclusion of patient-oriented outcomes (POEMs)
related to CM. All trials were researched via PubMed, were published in in peer-reviewed
journals in English, met exclusion criteria including headaches, case studies, and articles
published prior to 2010. The three studies included in this selective EBM review are
randomized, double-blind controlled clinical trials published in years 2017, 2019, and 2020 using
the key words “fremanezumab” and “migraines” through the resource database PubMed.
Inclusion criteria included studies that were clinical trials, published from 2015-present,
and in the English language. Statistics reported and used include mean change from baseline,
standard error (SE), and p-values.
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Table 1. Demographics and Characteristics of Included Studies
Study

Type
RCT

#
Pts
509

Age
(yrs)
1870

Inclusion
Criteria
18-70 yrs,
Migraine onset
<50 years, in
good health,
migraine ≥ 12
months, chronic
migraine (CM)
criteria. Patients
with or without
overuse of acute
headache
medicine,
documented
failure of 2-4 of
the preventative
treatments.

Ferarri2
2019

Silberstein3
2017

RCT

755

1870

Goadsby6
2020

RCT

1110

1870

18-70 yrs,
migraine ≥12
months, CM
criteria, 30% of
trial participants
allowed stable
dose of one
migrainepreventative
medications for
at least 2 months
prior to
preintervention
period
18-70 yrs,
migraine ≥12
months, CM
criteria*, max of
1 migraine
preventative
medication for
rollover patients
or 2 for new
patients if dosage
stable for ≥ 2
months.

Exclusion Criteria

W/D

Interventions

Current use of migraine
preventative
medications,
onabotulinumtoxinA ≤ 3
months prior to
screening, opioid or
barbiturate containing
treatments > 4 d/mo
prior to screening,
interventions or devices
for migraine <2 months
before screening of
NSAIDs on almost daily
basis for other
indication, prior
exposure to monoclonal
antibody
OnabotulinumtoxinA
during 4 months prior to
screening, use of
interventions or devices
for migraine (nerve
blocks, transcranial
magnetic stimulation
during 2 months before
screening), opiod or
barbiturate medications
>4 d/mo during
preintervention period

15

Quarterly Vs
Monthly
fremanezumab
SQ Injection

20

Quarterly vs
Monthly
fremanezumab
SQ Injection

OnabotulinumtoxinA
during 4 months prior to
screening, use of
interventions or devises
for migraine (nerve
blocks, transcranial
magnetic stimulation
during 2 months before
screening), opiod or
barbiturate medications
>4 d/mo during
preintervention period,
prior failure of ≥ 2
preventative medications
after adequate
therapeutic trial *only for
rollover HALO patients

237

Quarterly vs
Monthly
fremanezumab
SQ Injection
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The selected studies, detailed in Table 1, include a population of patients diagnosed with
CM who were treated with the intervention of quarterly fremanezumab subcutaneous injections
of 675 mg at month 1, 225 mg placebo month 2, and 225 mg placebo month 3 and compared to
patients with CM that were treated with monthly fremanezumab subcutaneous injections of 675
mg at month one, 225 mg fremanezumab month 2, and 225 mg fremanezumab month 3.
Inclusion and exclusion criteria varied slightly between each study but were largely similar. The
measured outcome was the mean change from baseline in the number of migraine days per
month.
OUTCOMES:
In all three RCTs, patient data was collected using daily, participant self-reported
electronic headache diary and outcome measured was the mean change from baseline in the
average number of migraine days per month during the 12-week treatment period after the first
administered dose of fremanezumab. Silberstein et al., Ferrari et al., and Goadsby et al. defined
migraine days as a calendar day with ≥ 4 hours of consecutive headache pain or calendar day
with migraine-specific medication use (triptan or ergot) for headache treatment.2.3.6
RESULTS:
The Silberstein et al. (2017) study was a randomized, double-blind, parallel-group trial
that took place in nine countries at 132 clinics that treated individuals with headaches. Patients
were 18-70 years old, had at least a 12-month history of migraine, and met the criteria for
chronic migraine during the 28-day preintervention period.3 CM criteria was defined as
“…headache of any duration or severity on ≥15 days and headache meeting ICHD-3 beta criteria
for migraine on ≥8 days.”3
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Of note for this study, 30% of patients on a stable-dose of migraine-preventative
medication were allowed to continue these medications if they had been on a stable dose ≥2
months prior to the preintervention period. 3 Randomized allocation concealment was achieved
at a 1:1 ratio via “electronic interactive-response technology, with stratification according to sex,
country, and baseline use of preventative medication (yes or no).”3
Patients in the intervention group received a baseline fremanezumab dose of 675 mg
administered followed by a single placebo injection at weeks 4 and 8.3 In the comparison group,
participants received a baseline fremanezumab dose of 675 mg followed by one, 225 mg
injection of fremanezumab at weeks 4 and 8.3 Data were collected daily through a participant,
self-reported headache diary with a final evaluation of the mean change in the average number of
migraine days from the baseline 28 day preintervention period occuring at week 12.
Table 2 demonstrates the mean (±SE) change from baseline in the average number of
migraine days per month in the intervention group of quarterly fremanezumab (-4.9 ± 0.4) and in
the comparison group of monthly fremanezumab (-5.0 ± 0.4).3 The p-value is reported at
p˂0.001 with a CI of 95% for both groups (numeric range not provided), indicating that the
reduction in migraine days between quarterly and monthly fremanezumab was statistically
significant and the treatments were not as effective in the quarterly fremanezumab group.3
Discontinuation rates were low in both groups: 1% of quarterly and 2% of monthly patients.
Table 2. Mean Change from Baseline in Average Number of Migraine Days Per Month in
Silberstein et al. 2017 Study
Fremanezumab

Migraine days during
28-day preintervention
period

Quarterly (n=375)
Monthly (n=375)

16.2 ± 4.9
16.0 ± 5.2

Mean change from baseline in
Average # of Migraine days per
month post 12-week treatment
period
-4.9 ± 0.4
-5.0 ± 0.4

Pvalue
<0.001
<0.001
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Ferrari et al. (2019) was a randomized, double-blind, parallel group trial where
participants were assigned at random in a 1:1 ratio to quarterly and monthly fremanezumab
injections via “electronic interactive response technology.”2 This clinical trial included 104 sites
spanning 14 countries and patients that met the CM criteria that were between the ages of 18-70.
Failure of 2-4 classes of migraine preventive medications within past decade was a notable
inclusion criterion for the trial participants which differs from the 2017 Silberstein et al. study.
Exclusion criterion included use of migraine preventative medication, which is another
difference between Ferrari et al. (2019) and Silberstein et al. (2017).2 Data was similarly
collected via daily electronic self-reported headache diary entries.
This 2019 trial used the same intervention and comparison medication dosage and
administration as the previously discussed trial. The quarterly group received a 675 mg dose of
fremanezumab at baseline followed by single placebo injections at weeks 4 and 8 and the
monthly group received a 675 mg dose at baseline followed by a single subcutaneous injection of
225 mg fremanezumab at weeks 4 and 8.2
Patients in the intervention group of quarterly fremanezumab had a mean (±SE) change
from baseline in the average number of migraine days per month of -3.9 ± 0.3 and patients in the
comparison group of monthly fremanezumab had a mean change from baseline in the average
number of migraine days per month of -4.5 ± 0.3 (Table 3).2 The p-value is reported at p˂0.0001
with a CI of 95% for both groups (numeric range not provided), indicating that the reduction in
migraine days between quarterly and monthly fremanezumab was statistically significant and the
treatments were not as effective in patients with CM receiving quarterly fremanezumab, resulting
in a small treatment effect.2 Additionally, this study also reported the mean percentage change
from baseline among quarterly (-34.9% (31.7)), and monthly (-36.8% (32.1)) fremanezumab
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groups for monthly average migraine days, indicating quarterly injections were not as effective
as monthly injections.2 More than 97% of the participants completed the study (544/559).2
Table 3. Mean Change from Baseline in Average Number of Migraine Days Per Month in
Ferrari et al. 2019 Study
Fremanezumab

Monthly Migraine
days at baseline
(Standard Deviation)

Quarterly (n=276) 14.1 (5.6)
Monthly (n=283) 14.1 (5.6)

Mean change from baseline in
Average # of Migraine days per
month post 12-week treatment
period
-3.9 ± 0.3
-4.5 ± 0.3

P-value

<0.0001
<0.0001

The final study for this review, Goadsby et al. (2020), was another randomized, doubleblind, parallel-group study where participants who met CM criteria were randomized in a 1:1
ratio into quarterly and monthly fremanezumab groups utilizing “interactive response
technology, with patients stratified by sex, country, and preventive medication use at baseline
(yes/no).”6 This study consisted of 135 sites across 9 countries and included participants from the
HALO efficacy studies as well as new participants.6 Data was, once again, collected through a
daily, electronic self-reported headache diary. Additional inclusion criteria for this RCT
consisted of the following: 18-70 years of age, ≥12 months history of migraine prior to
screening, and using no greater than 2 migraine preventative medications for new patients or a
maximum of 1 migraine preventative medication in rollover HALO patients.6 Unlike the two
previous trials (Silberstein et al. 2017, Ferrari et al. 2019), patient use of onabotulinumtoxinA,
opioids, barbiturates, previous failure of ≥ 2 preventive medications or use of an intervention or
device did not apply to new patients.6
Quarterly group participants received a baseline 675 mg dose of fremanezumab and a
single placebo at months 2 and 3.6 Monthly group participants received a baseline 675 mg dose
followed by a single 225 mg dose of fremanezumab at months 2 and 3.6
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Patients in the intervention group of quarterly fremanezumab had a mean (±SE) change
from baseline in the average number of migraine days per month of -6.0 ± 0.3 and patients in the
comparison group of monthly fremanezumab had a mean change from baseline in the average
number of migraine days per month of -6.5 ± 0.3 (Table 4).6 There were no reported p-values or
confidence intervals. However, this study did report the percentage of patients with at least a
50% reduction from baseline in the average monthly number of migraine days from quarterly
fremanezumab (42%) and monthly fremanezumab (48%), which resulted a NNT of 16. This
indicates that quarterly injections were not as effective as monthly injections. The
discontinuation rate in this study was the highest among the three RCTs reviewed with 21.4% of
study participants halting treatment.6 The top three reported reasons were withdrawing consent
(78/1110 patients), lack of efficacy (64/1110 patients), and adverse event (38/1110 patients).6
This trial length was longer in duration (12 months) than the two previously discussed 12 week
trials, which could explain the higher number of participants who discontinued the study. The
data from the week 12 evaluation was used for this EBM.
Table 4. Mean Change from Baseline in Average Number of Migraine Days Per Month in
Goadsby et al. 2020 Study
Fremanezumab

Monthly Migraine
days at baseline
(Standard Deviation)
Quarterly (n=551) 16.4 (5.1)
Monthly (n=559) 16.4 (5.3)

Mean (SE) change from baseline in Average
# of Migraine days per month post 12-week
treatment period
-6.0 ± 0.3
-6.5 ± 0.3

DISCUSSION:
Chronic migraine can be a debilitating condition where monoclonal antibodies against
CGRP, like fremanezumab, have been recently utilized successfully as preventative therapy to
decrease the number of migraine days per month and to improve patient quality of life.
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Traditionally, fremanezumab has been delivered as a once monthly subcutaneous injection. The
goal of this systematic review was to determine if quarterly fremanezumab was as effective as
the current practice of monthly fremanezumab in reducing the number of migraine days per
month in patients with CM so that patients could possibly benefit from decreased number of
injections, healthcare visits, and associated medical costs while effectively controlling their
condition.
All three selected studies had the comparison benefit of utilizing the same dosage,
frequency of administration, and route of administration. The studies also included the
generalizability benefit of being conducted in a large number of countries and facilities. The
Goadsby et al. 2020, Ferrari et al. 2019, and Silberstein et al. 2017 studies demonstrated a
difference in the reduction of migraine days from baseline between quarterly and monthly
fremanezumab administration with the outcomes favoring the monthly dosage. However, when
treating patients, it is also important to consider clinical significance. The differences between
the change from baseline in average number of migraine days per month between both groups in
all three studies are: 0.5 (Goadsby et. al 2020), 0.6 (Ferrari et al. 2019), and 0.1 (Silberstein et
al. 2017). With the outcomes reporting about half a day or less difference between quarterly and
fremanezumab groups, treatment frequency warrants a shared decision-making discussion with
patients where this data is presented.
Research on this topic was limited by the solitary use of PubMed as the source for
clinical trials. Generalizability was limited in all three studies due to the high number of female
participants and the inclusion criteria of relatively healthy individuals. These trial outcomes may
not be generalizable to individuals with additional comorbidities. The Silberstein et al. study
allowed up to 30% of the trial participants to utilize a migraine -preventative drug and was the
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only study to report a very close mean change from baseline in the number of migraine days
between the quarterly (-4.9 ± 0.4) and monthly (-5.0 ± 0.4) injections and may have altered the
outcome of the study. Another consideration when interpreting the data provided is that P-values
and confidence intervals were not provided for the Goadsby et al. study, which makes it difficult
to evaluate if the data provided was statistically significant. Additionally, Teva Pharmaceuticals
provided funding for all three studies and employees participated in the data analysis and
authoring of the trials. This limited the validity of the study results due to the possibility of bias.
CONCLUSION:
According to the results of this systematic review, quarterly fremanezumab is not as
effective as monthly administered fremanezumab at reducing the number of migraine days per
month individuals with chronic migraine. Statistically significant differences between both
groups were reported in the Ferrari et al. and Silberstein et al. studies with quarterly
fremanezumab having a lower reduction in the number of migraine days compared to monthly
fremanezumab. Similar results were found in the Goadsby et al. trial without reported p-value
and confidence interval precision measurements.
Further studies on fremanezumab should include varying doses, varying, frequency of
administration, and dual therapy with other preventative medications that have different
pharmacokinetics to cut down on the number of injections and cost associated with monthly
injections in patients with chronic migraine. An additional consideration is longer trial lengths
(>1 year). Future studies may also find it beneficial to evaluate of the use of fremanezumab in
populations with comorbidities.
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